Pfizer stock declines 10% within 6 months of reform passage

Pfizer, with a significant portion of revenue from high-margin drugs, would face pricing pressure from Trump-backed reforms. Analysts and investors would likely punish the stock given its exposure to US drug pricing policies, leading to a sustained decline.

Implied probability (Yes)

68%